Company: PFSA
Filing Date: 2025-10-29
Form Type: 424B3
Source: 0001213900-25-103174
Chunk: 4

Company: Profusa, Inc.
Filing Date: 2025-10-29
Form: 424B3
Chunk 4
---
 Combination”) with Profusa, Inc., a California corporation (“Profusa”),
pursuant to that certain Merger Agreement and Plan of Reorganization, dated as of November 7, 2022 (as the same has been amended,
supplemented or otherwise modified from time to time, the “Merger Agreement”), between the Company, Profusa, and NV Profusa
Merger Sub Inc., a Delaware corporation and a direct, wholly-owned subsidiary of the Company (“Merger Sub” and, collectively,
the “Parties”). The consummation of the Business Combination involved the merger (the “Merger”) of Merger Sub
with and into Profusa, pursuant to which, at the closing of the transactions contemplated by the Merger Agreement (the “Closing”),
the separate corporate existence of Merger Sub ceased, with Profusa as the surviving corporation becoming a wholly-owned subsidiary of
the Company, pursuant to the terms of the Merger Agreement and in accordance with the Delaware General Corporation Law (the “DGCL”). As
a result of the Business Combination, the Company owns 100% of the outstanding common stock of Profusa. In connection with the closing
of the Business Combination, the Company changed its name from “NorthView Acquisition Corporation” to “Profusa, Inc.”

Profusa, Inc. was incorporated
in the state of California on May 11, 2009. The Company is engaged in the development of a new generation of biointegrated sensors
that potentially empowers the individual with the ability to monitor their unique body chemistry.

The Company’s technology
enables the development of bioengineered sensors that are designed to become one with the body to detect and continuously transmit actionable,
clinical-grade data for personal and medical use. The Company’s first offering in the European Union, the Lumee™ Oxygen Platform,
is designed to report reliable tissue oxygen levels at various regions of interest, both acutely and long-term. The Lumee™ Oxygen
Platform has been designed for use in applications where monitoring of compromised tissue is beneficial, such as peripheral artery disease
that results in narrowing of blood vessels and reduced blood flow to the lower limbs; chronic wounds (diabetic ulcers, pressure sores)
that do not heal properly; and reconstructive surgery.

The Company’s research
and development efforts are primarily focused on its Lumee™ Glucose Platform, which is a system designed to monitor glucose levels
in interstitial fluid, continuously and long-term. A tiny, biocompatible gel injected under